Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Gurdip Bhalay is active.

Publication


Featured researches published by Gurdip Bhalay.


Journal of Pharmacology and Experimental Therapeutics | 2009

Camostat attenuates airway epithelial sodium channel function in vivo through the inhibition of a channel-activating protease

Kevin Coote; Hazel C. Atherton-Watson; Rosemary Sugar; Alice Young; Andrea MacKenzie-Beevor; Martin Gosling; Gurdip Bhalay; Graham Charles Bloomfield; Andrew Dunstan; Robert J. Bridges; Juan R. Sabater; William M. Abraham; David C. Tully; Ray Pacoma; Andrew M. Schumacher; Jennifer L. Harris; Henry Danahay

Inhibition of airway epithelial sodium channel (ENaC) function enhances mucociliary clearance (MCC). ENaC is positively regulated by channel-activating proteases (CAPs), and CAP inhibitors are therefore predicted to be beneficial in diseases associated with impaired MCC. The aims of the present study were to 1) identify low-molecular-weight inhibitors of airway CAPs and 2) to establish whether such CAP inhibitors would translate into a negative regulation of ENaC function in vivo, with a consequent enhancement of MCC. To this end, camostat, a trypsin-like protease inhibitor, provided a potent (IC50 ∼50 nM) and prolonged attenuation of ENaC function in human airway epithelial cell models that was reversible upon the addition of excess trypsin. In primary human bronchial epithelial cells, a potency order of placental bikunin > camostat > 4-guanidinobenzoic acid 4-carboxymethyl-phenyl ester > aprotinin >> soybean trypsin inhibitor = α1-antitrypsin, was largely consistent with that observed for inhibition of prostasin, a molecular candidate for the airway CAP. In vivo, topical airway administration of camostat induced a potent and prolonged attenuation of ENaC activity in the guinea pig trachea (ED50 = 3 μg/kg). When administered by aerosol inhalation in conscious sheep, camostat enhanced MCC out to at least 5 h after inhaled dosing. In summary, camostat attenuates ENaC function and enhances MCC, providing an opportunity for this approach toward the negative regulation of ENaC function to be tested therapeutically.


Tetrahedron Letters | 1997

Solid-phase synthesis of diverse tetrahydro-1,4-benzodiazepine-2-ones

Gurdip Bhalay; Paul Blaney; Vanessa H. Palmer; Anthony David Baxter

Abstract A general method for the construction of tetrahydro-1,4-benzodiazepine-2-ones on solid-support has been developed utilising a cleavage-conjugate addition protocol as the key step in the design. Using this novel methodology the synthesis of a diverse one hundred and twenty compound library with three points of diversity has been achieved starting from readily available anthranilic esters.


Neurogastroenterology and Motility | 2012

Increased prokineticin 2 expression in gut inflammation: role in visceral pain and intestinal ion transport

Robert P. Watson; Elliot Lilley; Moh Panesar; Gurdip Bhalay; Steven Langridge; Shin-Shay Tian; Conor McClenaghan; Anna Ropenga; Fanning Zeng; Mark S. Nash

Background  Prokineticin 2 (PROK2) is an inflammatory cytokine‐like molecule expressed predominantly by macrophages and neutrophils infiltrating sites of tissue damage. Given the established role of prokineticin signaling on gastrointestinal function, we have explored Prok2 gene expression in inflammatory conditions of the gastrointestinal tract and assessed the possible consequences on gut physiology.


Bioorganic & Medicinal Chemistry Letters | 2002

8-Aryl xanthines potent inhibitors of phosphodiesterase 5.

Ruth Arnold; David Beer; Gurdip Bhalay; Urs Baettig; Stephen Paul Collingwood; Sarah Craig; Nicholas James Devereux; Andrew Dunstan; Angela Glen; Sylvie Gomez; Sandra Haberthuer; Trevor Howe; Stephen Jelfs; Heinz E. Moser; Reto Naef; Paul Leslie Nicklin; David Andrew Sandham; Rowan Stringer; Katharine L. Turner; Simon James Watson; Mauro Zurini

In clinical studies, several inhibitors of phosphodiesterase 5 (PDE5) have demonstrated utility in the treatment of erectile dysfunction. We describe herein a series of 8-aryl xanthine derivatives which function as potent PDE5 inhibitors with, in many cases, high levels of selectivity versus other PDE isoforms.


Tetrahedron Letters | 1998

FACILE SOLID PHASE SYNTHESIS OF AN ACTIVATED DIAZO LINKER

Gurdip Bhalay; Andrew Dunstan

Abstract The synthesis of a resin bound diazo species has been achieved in a highly efficient manner starting from commercially available reagents. This has produced an activated linker, providing a chemoselective method for the attachment of functionalised carboxylic acids to the solid phase via the Wang linker, in a rapid and colourometric reaction.


Molecular Diversity | 1997

Multiple solid-phase synthesis of hydantoins and thiohydantoins

Gurdip Bhalay; Daniel Cowell; Neal D Hone; Martin Scobie; Anthony David Baxter

A novel general protocol for the construction of hydantoins and thiohydantoins on a solid support has been developed. Using this novel methodology, the synthesis of a diverse 96-compound library has been achieved. Resin-bound dipeptides are cyclised via the formation of an intermediate isocyanate or isothiocyanate on resin as the key step in the strategy.


Bioorganic & Medicinal Chemistry Letters | 2002

A solid-phase approach towards the synthesis of PDE5 inhibitors

David Beer; Gurdip Bhalay; Andrew Dunstan; Angela Glen; Sandra Haberthuer; Heinz E. Moser

PDE5 inhibitors based upon the xanthine scaffold 8 have been expediently synthesized using a solid-phase route. Attachment of the xanthine scaffold 8 using the Rink chloride linker 4 and N-1 functionalization using Mitsunobu chemistry is described. A library of compounds was produced in multi-milligram quantities with excellent purities and acceptable yields. The compounds were tested for their PDE5 inhibitory activity.


Chemical Communications | 2003

Dyad beads and the combinatorial discovery of catalysts

Iain Lingard; Gurdip Bhalay; Mark Bradley

Dyad beads, bearing both a substrate and a catalyst, were prepared to enable direct split and mix bead based screening for catalysis.


Assay and Drug Development Technologies | 2014

The development of automated patch clamp assays for canonical transient receptor potential channels TRPC3, 6, and 7.

Mark McPate; Gurdip Bhalay; Martin Beckett; Sian Fairbrother; Martin Gosling; Paul J. Groot-Kormelink; Rebecca Lane; Toby C. Kent; Michiel T. van Diepen; Pamela Tranter; J. Martin Verkuyl

The canonical transient receptor potential channel subfamily (TRPC3, TRPC6, and TRPC7) contains Ca(2+) permeable non-selective cation channels that are widely expressed in a variety of tissues. There is increasing evidence implicating TRPC channels, particularly TRPC3 and 6, in physiological and pathophysiological processes, eliciting interest in these channels as novel drug targets. Electrophysiology remains a benchmark technique for measuring ion channel function and accurately determining the pharmacological effects of compounds. In this report we describe the development of TRPC inhibitor assays on 2 automated planar patch clamp platforms-the IonWorks(®) Quattro™ and QPatch(®) systems. To enable activation of TRPC channels by carbachol, Chinese Hamster Ovary-K1 cells stably expressing the muscarinic M3 receptor were transduced with human TRPC3, TRPC6, or TRPC7 using BacMam viruses. TRPC3, 6, and 7 currents could be recorded on both platforms. However, the design of each platform limits which assay parameters can be recorded. Due to its continuous recording capabilities, the QPatch can capture both the activation and decay of the response. However, the transient nature of TRPC channels, the inability to reactivate and the large variation in peak currents limits the ability to develop assays for compound screening. The IonWorks Quattro, due to its discontinuous sampling, did not fully capture the peak of TRPC currents. However, due to the ability of the IonWorks Quattro to record from 64 cells per well, the variation from well to well was sufficiently reduced allowing for the development of medium-throughput screening assays.


Bioorganic & Medicinal Chemistry Letters | 2011

Design and synthesis of a library of chemokine antagonists.

Gurdip Bhalay; Birgit Albrecht; Mohammed Akhlaq; Urs Baettig; David Beer; Zarin Brown; Steven J. Charlton; Andrew Dunstan; Michelle Bradley; Peter Gedeck; Angela Glen; Trevor Howe; Thomas H. Keller; Juliet Leighton-Davies; Alice Li; Clive Mccarthy; Cecile Mocquet; Charles Owen; Paul Leslie Nicklin; Elizabeth M. Rosethorne

A library of chemokine antagonists has been synthesized using a combination of solid and solution-phase chemistry. Structures of known chemokine antagonists were used to produce a pharmacophore which served to guide monomer selection. Several combinations of monomers have resulted in providing novel chemokine antagonists which in some cases display dual chemokine receptor antagonism.

Collaboration


Dive into the Gurdip Bhalay's collaboration.

Researchain Logo
Decentralizing Knowledge